About
What it is and where it shows up.
Soy protein isolate (SPI) is a highly refined protein ingredient derived from defatted soybean flour, containing at least 90% protein on a dry-weight basis. It is widely used as a protein fortifier, emulsifier, and texturizer in processed foods, meat analogues, infant formulas, protein powders, and nutritional beverages.
Safety summary
The regulatory and scientific consensus.
SPI is broadly approved as safe for the general population and is affirmed GRAS under US FDA regulations (21 CFR 184.1553); however, soy is classified as one of eight major food allergens mandating label declaration under both US and EU law. SPI retains isoflavones (phytoestrogens such as genistein and daidzein) that may interfere with thyroid hormone synthesis and absorption of levothyroxine in susceptible individuals. In 2019, the FDA revoked its authorized health claim linking soy protein to reduced coronary heart disease risk, citing a lack of significant scientific agreement among qualified experts.
Regulatory landscape
What food-safety regulators have decided.
| Jurisdiction | Status | Note |
|---|---|---|
| EFSA (European Food Safety Authority) (European Union) | Approved | Approved as a food ingredient; not classified as a food additive, therefore carries no E-number. Soy is a mandatory allergen under Regulation (EU) No 1169/2011 Annex II, requiring label declaration. EFSA NDA Panel (2017 draft opinion) concluded that safety and suitability of soy protein isolate-based follow-on formula for infants cannot be established with currently available data. Health claim linking ISP to LDL-cholesterol reduction was evaluated under Regulation (EC) No 1924/2006 but not granted as an authorized claim.source |
| FSSAI (Food Safety and Standards Authority of India) (India) | Approved | Soya protein isolate/edible legume seed protein isolate is listed as a permitted ingredient in health supplements and nutraceuticals under FSSAI Health Supplement Regulations (Schedule listing item 176). FSSAI does not currently permit ingredients of GM origin under FSSR; most commercial SPI is derived from GM soy, requiring non-GM sourcing for regulatory compliance. A draft 2024 FSSAI amendment addresses updated standards for textured soy protein.source |
| FDA (Food and Drug Administration) (United States) | Approved | Affirmed GRAS under 21 CFR 184.1553 as a nutrient supplement with no established ADI. Soy is a declared major food allergen under FALCPA (21 U.S.C. §343(w)); mandatory label declaration required. FDA revoked the authorized health claim linking soy protein to reduced CHD risk in 2019 (21 CFR 101.82), replacing it with a qualified health claim with appropriate caveats.source |
Who should approach with care
Whose guidance would steer them away.
Other — Individuals with a confirmed soy allergy must strictly avoid soy protein isolate, as soy is designated one of the eight major food allergens under US FDA (FALCPA) and is listed in Annex II of EU Regulation (EU) No 1169/2011, mandating label declaration due to risk of serious allergic reactions.
Infants — EFSA's NDA Panel (2017) concluded that safety and suitability of soy protein isolate-based follow-on formula cannot be established with available data, and use in infant or follow-on formula requires clinical evaluation and medical supervision per EU infant formula legislation (Delegated Regulation (EU) 2016/127).
Thyroid Disease — Isoflavones (genistein, daidzein) retained in SPI may inhibit thyroid peroxidase and interfere with intestinal absorption of levothyroxine in hypothyroid patients, potentially necessitating dose adjustment; timing of SPI consumption relative to thyroid medication intake should be managed under medical guidance.
Children — High-dose supplemental intake of soy isoflavones present in SPI raises concerns about potential endocrine-disrupting effects in young children; standard dietary amounts in conventional foods are generally considered acceptable, but concentrated protein supplements warrant caution in paediatric populations.
Research citations
The sources behind this verdict.
- 1FDA. Title 21 CFR Part 184.1553 – Soy Protein Isolate (GRAS Affirmation). accessdata.fda.gov
- 2FSSAI. Implementation of Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food Regulations, 2016, 2018. fssai.gov.in
- 3FDA. Food Labeling: Soy Protein and Coronary Heart Disease – Preliminary Regulatory Impact Analysis (Proposed Rule), 2017. fda.gov
- 4EFSA. Draft Scientific Opinion on the safety and suitability of soy protein isolates for use in follow-on formulae for infants, 2017. efsa.europa.eu
- 5EFSA. Scientific Opinion on the substantiation of a health claim related to isolated soy protein (ISP) and reduction of blood LDL-cholesterol concentrations, 2012. efsa.europa.eu
Independently researched5 citations